KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Non-Current Deffered Revenue (2018 - 2025)

Historic Non-Current Deffered Revenue for Vir Biotechnology (VIR) over the last 8 years, with Q3 2025 value amounting to $9.4 million.

  • Vir Biotechnology's Non-Current Deffered Revenue changed N/A to $9.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.4 million, marking a year-over-year change of. This contributed to the annual value of $1.5 million for FY2023, which is 9713.2% down from last year.
  • Latest data reveals that Vir Biotechnology reported Non-Current Deffered Revenue of $9.4 million as of Q3 2025.
  • In the past 5 years, Vir Biotechnology's Non-Current Deffered Revenue ranged from a high of $55.5 million in Q2 2021 and a low of $1.5 million during Q4 2023
  • For the 5-year period, Vir Biotechnology's Non-Current Deffered Revenue averaged around $25.5 million, with its median value being $7.6 million (2022).
  • As far as peak fluctuations go, Vir Biotechnology's Non-Current Deffered Revenue soared by 135467.89% in 2021, and later plummeted by 9713.2% in 2023.
  • Quarter analysis of 5 years shows Vir Biotechnology's Non-Current Deffered Revenue stood at $3.8 million in 2021, then skyrocketed by 1294.68% to $53.2 million in 2022, then crashed by 97.13% to $1.5 million in 2023, then changed by 0.0% to $1.5 million in 2024, then skyrocketed by 518.15% to $9.4 million in 2025.
  • Its last three reported values are $9.4 million in Q3 2025, $1.5 million for Q1 2024, and $1.5 million during Q4 2023.